{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T15:35:45Z","timestamp":1792683345859,"version":"4.5.0"},"reference-count":61,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T00:00:00Z","timestamp":1768348800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01HL146559"],"award-info":[{"award-number":["R01HL146559"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01HL130028"],"award-info":[{"award-number":["R01HL130028"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01HL148280"],"award-info":[{"award-number":["R01HL148280"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01HL153047"],"award-info":[{"award-number":["R01HL153047"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01HL177904"],"award-info":[{"award-number":["R01HL177904"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01AI181792"],"award-info":[{"award-number":["R01AI181792"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000968","name":"American Heart Association","doi-asserted-by":"publisher","award":["POST1011698"],"award-info":[{"award-number":["POST1011698"]}],"id":[{"id":"10.13039\/100000968","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000968","name":"American Heart Association","doi-asserted-by":"publisher","award":["POST1189050"],"award-info":[{"award-number":["POST1189050"]}],"id":[{"id":"10.13039\/100000968","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000968","name":"American Heart Association","doi-asserted-by":"publisher","award":["POST1410518"],"award-info":[{"award-number":["POST1410518"]}],"id":[{"id":"10.13039\/100000968","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,26]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Sodium-glucose co-transporter 2 inhibitors are widely used to treat patients with type 2 diabetes and exhibit beneficial cardiovascular effects beyond glucose lowering. In this study, we investigated their potential to alleviate vaso-occlusive events and organ damage in sickle cell disease (SCD) mice.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>Intravital and immunofluorescence microscopy reveal that a 4-day oral administration of dapagliflozin (DAPA) or sotagliflozin (SOTA) significantly reduces neutrophil adhesion and transmigration in cremaster venules, with SOTA showing greater inhibition, and down-regulates E-selectin and intercellular adhesion molecule-1 (ICAM-1) expression in cremaster venules of TNF-\u03b1-challenged SCD mice. Intriguingly, only SOTA improves mouse survival acutely. Similar inhibitory effects on neutrophil recruitment are observed in SCD mice subjected to hypoxia-reoxygenation. Flow chamber assays indicate that neither drug directly affects neutrophil or endothelial cell adhesive function. In addition, treatment of neutrophils and platelets from SCD mice and patients with DAPA or SOTA does not affect their activation. When administered for 4 months, DAPA or SOTA mitigates neutrophil recruitment and enhances microcirculation in cremaster venules of TNF-\u03b1-challenged SCD mice, while only SOTA confers a survival benefit. Both drugs reduce leucocyte infiltration in the liver or lungs, suggesting their ability to protect against organ damage. Co-administration with hydroxyurea for 4 months does not enhance these effects. Multiplex analysis shows that DAPA and SOTA lower plasma levels of soluble P-selectin, ICAM-1, S100A8\/A9, and pro-inflammatory cytokines in SCD mice.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our findings suggest that DAPA and SOTA mitigate vaso-occlusive events in SCD, with SOTA providing superior benefits.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/cvr\/cvag003","type":"journal-article","created":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T12:29:25Z","timestamp":1768307365000},"page":"651-664","source":"Crossref","is-referenced-by-count":3,"title":["Beneficial effects of SGLT1\/2 and SGLT2 inhibitors on vaso-occlusive events and organ damage in sickle cell disease mice"],"prefix":"10.1093","volume":"122","author":[{"given":"Bo-Ram","family":"Jin","sequence":"first","affiliation":[{"name":"Division of Hematology, Department of Medicine, Washington University School of Medicine , St. Louis, MO 63110 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tripti","family":"Kumari","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine, Washington University School of Medicine , St. Louis, MO 63110 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingu","family":"Lee","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine, Washington University School of Medicine , St. Louis, MO 63110 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae-Sung","family":"Kim","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine, Washington University School of Medicine , St. Louis, MO 63110 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radka","family":"Bokorova","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine, Washington University School of Medicine , St. Louis, MO 63110 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atish","family":"Gheware","sequence":"additional","affiliation":[{"name":"Division of Pulmonary and Critical Care Medicine, Department of Medicine, Washington University in St. Louis , St. Louis, MO 63110 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla Valenzuela","family":"Ripoll","sequence":"additional","affiliation":[{"name":"Cardiovascular Division, Department of Medicine, Washington University School of Medicine , St. Louis, MO 63110 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alireza","family":"Sargazi","sequence":"additional","affiliation":[{"name":"Cardiovascular Division, Department of Medicine, Washington University School of Medicine , St. Louis, MO 63110 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soi","family":"Jeong","sequence":"additional","affiliation":[{"name":"Department of Anatomy, Graduate School of Medical Science, Brain Korea 21 Project, Yonsei University College of Medicine , Seoul ,","place":["Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young-Min","family":"Hyun","sequence":"additional","affiliation":[{"name":"Department of Anatomy, Graduate School of Medical Science, Brain Korea 21 Project, Yonsei University College of Medicine , Seoul ,","place":["Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sana","family":"Saif Ur Rehman","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine, Washington University School of Medicine , St. Louis, MO 63110 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Babak","family":"Razani","sequence":"additional","affiliation":[{"name":"Department of Medicine, Vascular Medicine Institute, University of Pittsburgh School of Medicine , Pittsburgh, PA 15213 ,","place":["USA"]},{"name":"Division of Cardiology, Pittsburgh VA Medical Center , Pittsburgh, PA 15240 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6812-6043","authenticated-orcid":false,"given":"Janet S","family":"Lee","sequence":"additional","affiliation":[{"name":"Division of Pulmonary and Critical Care Medicine, Department of Medicine, Washington University in St. Louis , St. Louis, MO 63110 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Javaheri","sequence":"additional","affiliation":[{"name":"Cardiovascular Division, Department of Medicine, Washington University School of Medicine , St. Louis, MO 63110 ,","place":["USA"]},{"name":"John Cochran VA Hospital , St. Louis, MO 63110"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2404-3446","authenticated-orcid":false,"given":"Jaehyung","family":"Cho","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine, Washington University School of Medicine , St. Louis, MO 63110 ,","place":["USA"]},{"name":"Department of Pathology and Immunology, Washington University School of Medicine , St. Louis, MO 63110 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,1,14]]},"reference":[{"key":"2026032612474381100_cvag003-B1","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1038\/180326a0","article-title":"Gene mutations in human haemoglobin: the chemical difference between normal and sickle cell haemoglobin","volume":"180","author":"Ingram","year":"1957","journal-title":"Nature"},{"key":"2026032612474381100_cvag003-B2","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1056\/NEJMra1510865","article-title":"Sickle Cell Disease","volume":"376","author":"Piel","year":"2017","journal-title":"N Engl J Med"},{"key":"2026032612474381100_cvag003-B3","doi-asserted-by":"crossref","first-page":"3892","DOI":"10.1182\/blood-2013-05-498311","article-title":"Vaso-occlusion in sickle cell disease: pathophysiology and novel targeted therapies","volume":"122","author":"Manwani","year":"2013","journal-title":"Blood"},{"key":"2026032612474381100_cvag003-B4","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1111\/j.1600-0609.2011.01647.x","article-title":"Acute chest syndrome: sickle cell disease","volume":"87","author":"Paul","year":"2011","journal-title":"Eur J Haematol"},{"key":"2026032612474381100_cvag003-B5","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1182\/blood-2005-07-2839","article-title":"Pathology of Berkeley sickle cell mice: similarities and differences with human sickle cell disease","volume":"107","author":"Manci","year":"2006","journal-title":"Blood"},{"key":"2026032612474381100_cvag003-B6","doi-asserted-by":"crossref","first-page":"e20211083","DOI":"10.1084\/jem.20211083","article-title":"Neutrophil DREAM promotes neutrophil recruitment in vascular inflammation","volume":"219","author":"Li","year":"2022","journal-title":"J Exp Med"},{"key":"2026032612474381100_cvag003-B7","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1038\/nm.1939","article-title":"Heterotypic interactions enabled by polarized neutrophil microdomains mediate thromboinflammatory injury","volume":"15","author":"Hidalgo","year":"2009","journal-title":"Nat Med"},{"issue":"7","key":"2026032612474381100_cvag003-B8","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1056\/NEJMoa1512021","article-title":"A Multinational Trial of Prasugrel for Sickle Cell Vaso-Occlusive Events","volume":"374","author":"Heeney","year":"2016","journal-title":"N Engl J Med"},{"issue":"2","key":"2026032612474381100_cvag003-B9","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1111\/bjh.15646","article-title":"Ticagrelor does not impact patient-reported pain in young adults with sickle cell disease: a multicentre, randomised phase IIb study","volume":"184","author":"Kanter","year":"2019","journal-title":"Br J Haematol"},{"key":"2026032612474381100_cvag003-B10","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1182\/blood.2021014095","article-title":"Ticagrelor vs placebo for the reduction of vaso-occlusive crises in pediatric sickle cell disease: the HESTIA3 study","volume":"140","author":"Heeney","year":"2022","journal-title":"Blood"},{"key":"2026032612474381100_cvag003-B11","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1056\/NEJMoa1611770","article-title":"Crizanlizumab for the Prevention of Pain Crises in Sickle Cell Disease","volume":"376","author":"Ataga","year":"2017","journal-title":"N Engl J Med"},{"key":"2026032612474381100_cvag003-B12","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/ajh.25308","article-title":"Effect of crizanlizumab on pain crises in subgroups of patients with sickle cell disease: A SUSTAIN study analysis","volume":"94","author":"Kutlar","year":"2019","journal-title":"Am J Hematol"},{"key":"2026032612474381100_cvag003-B13","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1002\/ajh.27275","article-title":"Crizanlizumab and sickle cell disease: When should medications have their approval status revoked?","volume":"99","author":"Jacobs","year":"2024","journal-title":"Am J Hematol"},{"key":"2026032612474381100_cvag003-B14","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1056\/NEJMoa2031054","article-title":"CRISPR-Cas9 Gene Editing for Sickle Cell Disease and beta-Thalassemia","volume":"384","author":"Frangoul","year":"2021","journal-title":"N Engl J Med"},{"issue":"7","key":"2026032612474381100_cvag003-B15","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2117175","article-title":"Biologic and Clinical Efficacy of LentiGlobin for Sickle Cell Disease","volume":"386","author":"Kanter","year":"2022","journal-title":"N Engl J Med"},{"key":"2026032612474381100_cvag003-B16","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.ymthe.2024.01.015","article-title":"A new frontier: FDA approvals for gene therapy in sickle cell disease","volume":"32","author":"Leonard","year":"2024","journal-title":"Mol Ther"},{"key":"2026032612474381100_cvag003-B17","doi-asserted-by":"crossref","first-page":"108330","DOI":"10.1016\/j.pharmthera.2022.108330","article-title":"Sodium-glucose co-transporter 2 inhibitors in patients with chronic kidney disease","volume":"242","author":"Solomon","year":"2023","journal-title":"Pharmacol Ther"},{"issue":"12","key":"2026032612474381100_cvag003-B18","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction","volume":"387","author":"Solomon","year":"2022","journal-title":"N Engl J Med"},{"issue":"16","key":"2026032612474381100_cvag003-B19","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in Heart Failure with a Preserved Ejection Fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"key":"2026032612474381100_cvag003-B20","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2030183","article-title":"Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure","volume":"384","author":"Bhatt","year":"2021","journal-title":"N Engl J Med"},{"issue":"8 Pt 1","key":"2026032612474381100_cvag003-B21","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/j.jchf.2023.05.026","article-title":"Effect of Sotagliflozin on Early Mortality and Heart Failure-Related Events: A Post Hoc Analysis of SOLOIST-WHF","volume":"11","author":"Pitt","year":"2023","journal-title":"JACC Heart Fail"},{"key":"2026032612474381100_cvag003-B22","doi-asserted-by":"crossref","first-page":"15364","DOI":"10.1038\/s41598-021-94945-4","article-title":"Effects of SGLT2 inhibitors on stroke and its subtypes in patients with type 2 diabetes: a systematic review and meta-analysis","volume":"11","author":"Tsai","year":"2021","journal-title":"Sci Rep"},{"key":"2026032612474381100_cvag003-B23","doi-asserted-by":"crossref","first-page":"865","DOI":"10.33594\/000000178","article-title":"Empagliflozin and Dapagliflozin Reduce ROS Generation and Restore NO Bioavailability in Tumor Necrosis Factor alpha-Stimulated Human Coronary Arterial Endothelial Cells","volume":"53","author":"Uthman","year":"2019","journal-title":"Cell Physiol Biochem"},{"key":"2026032612474381100_cvag003-B24","doi-asserted-by":"crossref","first-page":"5276","DOI":"10.1038\/s41598-018-23420-4","article-title":"Canagliflozin inhibits interleukin-1beta-stimulated cytokine and chemokine secretion in vascular endothelial cells by AMP-activated protein kinase-dependent and -independent mechanisms","volume":"8","author":"Mancini","year":"2018","journal-title":"Sci Rep"},{"key":"2026032612474381100_cvag003-B25","first-page":"101839","article-title":"Sodium-glucose co-transporter inhibition preserves apolipoprotein M (ApoM) during acute inflammation in mice and humans","volume":"4","author":"Ripoll","journal-title":"JACC: Advances"},{"key":"2026032612474381100_cvag003-B26","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s10787-020-00732-4","article-title":"Empagliflozin suppresses inflammation and protects against acute septic renal injury","volume":"29","author":"Maayah","year":"2021","journal-title":"Inflammopharmacology"},{"key":"2026032612474381100_cvag003-B27","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/S2213-8587(24)00218-3","article-title":"Effect of sodium-glucose co-transporter-2 inhibitors on survival free of organ support in patients hospitalised for COVID-19 (ACTIV-4a): a pragmatic, multicentre, open-label, randomised, controlled, platform trial","volume":"12","author":"Kosiborod","year":"2024","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026032612474381100_cvag003-B28","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1001\/jama.2024.10510","article-title":"Dapagliflozin for Critically Ill Patients With Acute Organ Dysfunction: The DEFENDER Randomized Clinical Trial","volume":"332","author":"Tavares","year":"2024","journal-title":"JAMA"},{"key":"2026032612474381100_cvag003-B29","doi-asserted-by":"crossref","first-page":"3442","DOI":"10.1210\/clinem\/dgac558","article-title":"Sodium-Glucose Cotransporter 2 Inhibitors and the Risk of Pneumonia and Septic Shock","volume":"107","author":"Li","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"2026032612474381100_cvag003-B30","doi-asserted-by":"crossref","first-page":"246","DOI":"10.3324\/haematol.2016.151159","article-title":"ARQ 092, an orally-available, selective AKT inhibitor, attenuates neutrophil-platelet interactions in sickle cell disease","volume":"102","author":"Kim","year":"2017","journal-title":"Haematologica"},{"key":"2026032612474381100_cvag003-B31","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1161\/CIRCULATIONAHA.124.070487","article-title":"Neutrophil CRACR2A Promotes Neutrophil Recruitment in Sterile Inflammation and Ischemic Stroke","volume":"151","author":"Lee","year":"2025","journal-title":"Circulation"},{"key":"2026032612474381100_cvag003-B32","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1182\/blood-2013-03-492504","article-title":"Platelet protein disulfide isomerase is required for thrombus formation but not essential for hemostasis in mice","volume":"122","author":"Kim","year":"2013","journal-title":"Blood"},{"key":"2026032612474381100_cvag003-B33","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1172\/JCI72305","article-title":"Neutrophil AKT2 regulates heterotypic cell-cell interactions during vascular inflammation","volume":"124","author":"Li","year":"2014","journal-title":"J Clin Invest"},{"key":"2026032612474381100_cvag003-B34","doi-asserted-by":"crossref","first-page":"101839","DOI":"10.1016\/j.jacadv.2025.101839","article-title":"Sodium-Glucose Cotransporter Inhibition Preserves Apolipoprotein M During Acute Inflammation in Mice and Humans","volume":"4","author":"Valenzuela Ripoll","year":"2025","journal-title":"JACC Adv"},{"key":"2026032612474381100_cvag003-B35","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/clpt.2012.58","article-title":"LX4211, a dual SGLT1\/SGLT2 inhibitor, improved glycemic control in patients with type 2 diabetes in a randomized, placebo-controlled trial","volume":"92","author":"Zambrowicz","year":"2012","journal-title":"Clin Pharmacol Ther"},{"key":"2026032612474381100_cvag003-B36","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1021\/jm701272q","article-title":"Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes","volume":"51","author":"Meng","year":"2008","journal-title":"J Med Chem"},{"key":"2026032612474381100_cvag003-B37","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1182\/blood-2015-02-626234","article-title":"Hydroxyurea with AKT2 inhibition decreases vaso-occlusive events in sickle cell disease mice","volume":"126","author":"Barazia","year":"2015","journal-title":"Blood"},{"key":"2026032612474381100_cvag003-B38","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1182\/blood-2009-12-260513","article-title":"GMI-1070, a novel pan-selectin antagonist, reverses acute vascular occlusions in sickle cell mice","volume":"116","author":"Chang","year":"2010","journal-title":"Blood"},{"key":"2026032612474381100_cvag003-B39","first-page":"2407","article-title":"Repurposing pyridoxamine for therapeutic intervention of intravascular cell-cell interactions in mouse models of sickle cell disease","volume":"105","author":"Li","year":"2020","journal-title":"Haematologica"},{"key":"2026032612474381100_cvag003-B40","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1038\/nm.2514","article-title":"The neutrophil in vascular inflammation","volume":"17","author":"Phillipson","year":"2011","journal-title":"Nat Med"},{"key":"2026032612474381100_cvag003-B41","doi-asserted-by":"crossref","first-page":"3107","DOI":"10.3390\/cells11193107","article-title":"Anti-Inflammatory Properties of the SGLT2 Inhibitor Empagliflozin in Activated Primary Microglia","volume":"11","author":"Heimke","year":"2022","journal-title":"Cells"},{"key":"2026032612474381100_cvag003-B42","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.3390\/ijms26041670","article-title":"Anti-Inflammatory Effects of SGLT2 Inhibitors: Focus on Macrophages","volume":"26","author":"Rykova","year":"2025","journal-title":"Int J Mol Sci"},{"key":"2026032612474381100_cvag003-B43","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1182\/blood-2012-02-409524","article-title":"Hydroxyurea and a cGMP-amplifying agent have immediate benefits on acute vaso-occlusive events in sickle cell disease mice","volume":"120","author":"Almeida","year":"2012","journal-title":"Blood"},{"key":"2026032612474381100_cvag003-B44","doi-asserted-by":"crossref","first-page":"e0270206","DOI":"10.1371\/journal.pone.0270206","article-title":"Stability evaluation of compounded hydroxyurea 100\u2005mg\/mL oral liquids using a novel analytical method involving chemical derivatization","volume":"17","author":"Coache","year":"2022","journal-title":"PLoS One"},{"key":"2026032612474381100_cvag003-B45","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1378\/chest.117.4.1162","article-title":"Anti-inflammatory cytokines","volume":"117","author":"Opal","year":"2000","journal-title":"Chest"},{"key":"2026032612474381100_cvag003-B46","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1056\/NEJMoa2030186","article-title":"Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease","volume":"384","author":"Bhatt","year":"2021","journal-title":"N Engl J Med"},{"key":"2026032612474381100_cvag003-B47","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/s12933-024-02210-5","article-title":"Sodium-glucose cotransporter 2 inhibitors, inflammation, and heart failure: a two-sample Mendelian randomization study","volume":"23","author":"Guo","year":"2024","journal-title":"Cardiovasc Diabetol"},{"key":"2026032612474381100_cvag003-B48","doi-asserted-by":"crossref","first-page":"17770","DOI":"10.1038\/s41598-024-84118-4","article-title":"SGLT2 inhibition mitigates intracerebral hemorrhage risk by modulating inflammation","volume":"15","author":"Huang","year":"2025","journal-title":"Sci Rep"},{"key":"2026032612474381100_cvag003-B49","doi-asserted-by":"crossref","first-page":"104870","DOI":"10.1016\/j.phrs.2020.104870","article-title":"Empagliflozin protects heart from inflammation and energy depletion via AMPK activation","volume":"158","author":"Koyani","year":"2020","journal-title":"Pharmacol Res"},{"key":"2026032612474381100_cvag003-B50","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.3390\/jcm12041356","article-title":"The Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitor Empagliflozin Reverses Hyperglycemia-Induced Monocyte and Endothelial Dysfunction Primarily through Glucose Transport-Independent but Redox-Dependent Mechanisms","volume":"12","author":"Semo","year":"2023","journal-title":"J Clin Med"},{"key":"2026032612474381100_cvag003-B51","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1161\/HYPERTENSIONAHA.122.19586","article-title":"SGLT2 Inhibition via Empagliflozin Improves Endothelial Function and Reduces Mitochondrial Oxidative Stress: Insights From Frail Hypertensive and Diabetic Patients","volume":"79","author":"Mone","year":"2022","journal-title":"Hypertension"},{"key":"2026032612474381100_cvag003-B52","doi-asserted-by":"crossref","first-page":"e70091","DOI":"10.1111\/jcmm.70091","article-title":"Inhibition of sodium-glucose cotransporter-2 improves anaemia in mice and humans with sickle cell disease, and reduces infarct size in a murine stroke model","volume":"28","author":"Wang","year":"2024","journal-title":"J Cell Mol Med"},{"key":"2026032612474381100_cvag003-B53","doi-asserted-by":"crossref","first-page":"107729","DOI":"10.1016\/j.jdiacomp.2020.107729","article-title":"Correction of anemia by dapagliflozin in patients with type 2 diabetes","volume":"34","author":"Stefansson","year":"2020","journal-title":"J Diabetes Complications"},{"key":"2026032612474381100_cvag003-B54","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1007\/s00125-018-4654-7","article-title":"Development of SGLT1 and SGLT2 inhibitors","volume":"61","author":"Rieg","year":"2018","journal-title":"Diabetologia"},{"key":"2026032612474381100_cvag003-B55","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.3390\/antiox11101878","article-title":"The Sodium-Glucose Co-Transporter-2 (SGLT2) Inhibitors Reduce Platelet Activation and Thrombus Formation by Lowering NOX2-Related Oxidative Stress: A Pilot Study","volume":"11","author":"Pignatelli","year":"2022","journal-title":"Antioxidants (Basel)"},{"key":"2026032612474381100_cvag003-B56","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.21037\/atm-20-7008","article-title":"Apolipoprotein M promotes the anti-inflammatory effect of high-density lipoprotein by binding to scavenger receptor BI","volume":"8","author":"Yao","year":"2020","journal-title":"Ann Transl Med"},{"key":"2026032612474381100_cvag003-B57","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1056\/NEJM199505183322001","article-title":"Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia","volume":"332","author":"Charache","year":"1995","journal-title":"N Engl J Med"},{"key":"2026032612474381100_cvag003-B58","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s13643-024-02461-z","article-title":"Role of hydroxyurea therapy in the prevention of organ damage in sickle cell disease: a systematic review and meta-analysis","volume":"13","author":"Khargekar","year":"2024","journal-title":"Syst Rev"},{"key":"2026032612474381100_cvag003-B59","doi-asserted-by":"crossref","first-page":"e0226583","DOI":"10.1371\/journal.pone.0226583","article-title":"Neutrophils remain detrimentally active in hydroxyurea-treated patients with sickle cell disease","volume":"14","author":"Barbu","year":"2019","journal-title":"PLoS One"},{"key":"2026032612474381100_cvag003-B60","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1111\/bjh.16003","article-title":"Rapid decline in estimated glomerular filtration rate is common in adults with sickle cell disease and associated with increased mortality","volume":"186","author":"Derebail","year":"2019","journal-title":"Br J Haematol"},{"key":"2026032612474381100_cvag003-B61","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1002\/ajh.27348","article-title":"GLP-1 agonists and SGLT-2 inhibitors in adults with sickle cell disease","volume":"99","author":"Sun","year":"2024","journal-title":"Am J Hematol"}],"container-title":["Cardiovascular Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cardiovascres\/advance-article-pdf\/doi\/10.1093\/cvr\/cvag003\/66405975\/cvag003.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cardiovascres\/article-pdf\/122\/5\/651\/66405975\/cvag003.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cardiovascres\/article-pdf\/122\/5\/651\/66405975\/cvag003.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T16:48:00Z","timestamp":1774543680000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cardiovascres\/article\/122\/5\/651\/8425119"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,14]]},"references-count":61,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,1,14]]},"published-print":{"date-parts":[[2026,3,26]]}},"URL":"https:\/\/doi.org\/10.1093\/cvr\/cvag003","relation":{},"ISSN":["0008-6363","1755-3245"],"issn-type":[{"value":"0008-6363","type":"print"},{"value":"1755-3245","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,3]]},"published":{"date-parts":[[2026,1,14]]}}}